Translate page

English English
en Englishbg Bulgarianzh-CN Chinese (Simplified)hr Croatiancs Czechda Danishnl Dutchfi Finnishfr Frenchde Germanel Greekiw Hebrewhi Hindiid Indonesianit Italianja Japaneseko Koreanmk Macedonianpl Polishpt Portuguesero Romanianru Russiansr Serbiansk Slovaksl Slovenianes Spanishsv Swedishth Thaitr Turkishvi Vietnamese

Ponatinib in pediatric patients with Philadelphia chromosome-positive leukemia: a retrospective survey of the Japan Children's Cancer Group (Kodama Y et al. Int J Hematol, July 2022)

Ponatinib in pediatric patients with Philadelphina chromosome-positive leukemia: a retrospective survey of the Japan Children’s Cancer Group
Kodama Y et al. Int J Hematol, July 2022

 

 

 

Sensoineural hearing loss in juvenile CML: A Rare Case Report in Surabaya, Indonesia (Syamsuddin IK and Notopuro PB, Int Med Case Rep J, July 2022)

Sensoineural hearing loss in juvenile CML: A Rare Case Report in Surabaya, Indonesia
Syamsuddin IK and Notopuro PB. Int Med Case Rep J, July 2022
– open access publication

Link to full abstract

 

 

 

Outcome prediction of chronic myeloid leukemia (CML) in children (Leung WY et al. Ann Hematol, June 2022)

Outcome prediction of chronic myeloid leukemia (CML) in children
Leung WY et al. Ann Hematol, June 2022 (epub ahead of print)

Link to full abstract

 

 

 

Successful eradication of chronic myeloid leukemia in a child despite allogeneic graft rejection (Vuorenoja S et al. Cancer Rep (Hoboken), July 2022)

Successful eradication of chronic myeloid leukemia in a child despite allogeneic graft rejection
Vuorenoja S et al. Cancer Rep (Hoboken), July 2022 (epub ahead of print)
– open access publication

Link to full abstract

 

 

 

Pediatric chronic myelogenous leukemia in T-lineage blast crisis: A reminder in relevance

Pediatric chronic myelogenous leukemia in T-lineage blast crisis: A reminder in relevance
Patel SA and Beck JC. J Pediatr Hematol Oncol, April 2022

Link to full abstract

 

 

 

  1. Distribution and frequency of tyrosine kinase inhibitor-associated long-term complications in children with chronic myeloid leukemia
  2. Discontinuation of tyrosine kinase inhibitors in pediatrc chronic myeloid leukemia (Shima H et al. Pediatr Blood Cancer, April 2022)
  3. Prognostic factors for outcomes of allogeneic HSCT for children and adolescents/young adults with CML in the TKI era (Shimada H et al. Transplant Cell Ther, April 2022)
  4. Skin and soft tissue infections in adolescent chronic myeloid leukemia under dasatanib treatment (Uchida E et al. Pediatr Blood Cancer, April 2022)